At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
Tislelizumabdrug
Likely dose
Tislelizumab 200 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Tislelizumab for Classical Hodgkin Lymphoma. Completed, enrolled 46 participants across 4 sites in 2 countries.
Detailed Summary
This was a Phase 2 trial evaluating the effectiveness and safety of tislelizumab in participants with relapsed or hard-to-treat classical Hodgkin lymphoma (cHL). Participants were grouped by prior treatments. The main outcome was to assess overall response rate (ORR) across both cohorts. Participants continued receiving the study treatment until their disease got worse, side effects became too severe, or they chose to stop for other reasons.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClassical Hodgkin Lymphoma
CountriesAustralia, United States
CollaboratorsLymphoma Study Association
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartAug 2020
Primary CompletionDec 2022
Study CompletionAug 2024
TodayJul 2026
First PostedMar 23, 2020
Enrollment StartAug 20, 2020
Primary CompletionDec 12, 2022
Study CompletionAug 29, 2024
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 6.3 years ago
Interventions
Tislelizumabdrug
200 milligrams (mg) intravenously every 3 weeks (Q3W)